XERIS PHARMACEUTICALS INC

🇺🇸United States
Ownership
-
Employees
-
Market Cap
$429.1M
Website

Safety and Efficacy of G-Pen Compared to Lilly Glucagon for Hypoglycemia Rescue in Adult Type 1 Diabetics

First Posted Date
2016-01-14
Last Posted Date
2018-10-30
Lead Sponsor
Xeris Pharmaceuticals
Target Recruit Count
80
Registration Number
NCT02656069
Locations
🇺🇸

University of Alabama at Birmingham, Birmingham, Alabama, United States

🇺🇸

ProSciento, Inc., Chula Vista, California, United States

🇺🇸

AMCR Institute, Escondido, California, United States

and more 4 locations

G-Penâ„¢ for Hypoglycemia Rescue in T1D Patients

Phase 2
Completed
Conditions
Interventions
First Posted Date
2015-04-22
Last Posted Date
2017-07-07
Lead Sponsor
Xeris Pharmaceuticals
Target Recruit Count
7
Registration Number
NCT02423980
Locations
🇺🇸

Diablo Clinical Research, Inc., Walnut Creek, California, United States

Safety and Efficacy Study of Mini-Dose Glucagon (G-Pen Mini) in Patients With Type 1 Diabetes

Phase 2
Completed
Conditions
Interventions
First Posted Date
2014-03-07
Last Posted Date
2018-04-05
Lead Sponsor
Xeris Pharmaceuticals
Target Recruit Count
13
Registration Number
NCT02081014
Locations
🇺🇸

Baylor College of Medicine, Children's Nutritional Research Center, Texas Children's Hospital, Houston, Texas, United States

PK/PD Study With G-Pump (Glucagon Infusion) in T1DM Patients

First Posted Date
2014-03-07
Last Posted Date
2018-04-06
Lead Sponsor
Xeris Pharmaceuticals
Target Recruit Count
19
Registration Number
NCT02081001
Locations
🇺🇸

Oregon Health & Science University, Portland, Oregon, United States

Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of G-Pen(TM) (Glucagon Injection) to Treat Severe Hypoglycemia

First Posted Date
2013-10-30
Last Posted Date
2016-02-03
Lead Sponsor
Xeris Pharmaceuticals
Target Recruit Count
30
Registration Number
NCT01972152
Locations
🇺🇸

Texas Diabetes Institute, University Health System, San Antonio, Texas, United States

© Copyright 2024. All Rights Reserved by MedPath